Over the last 40 years, we — as a society — have seen incredible progress in the way illnesses, such as cancer are treated. We owe these advances to medical research and the millions of patients who have volunteered to participate in clinical trials. As one of five global pharmaceutical Product Development sites, we contribute to all phases of clinical trial development, including overseeing clinical studies in Canada, the US and around the world.
In 2019, Roche invested more than $57 million in clinical research in Canada through 174 Roche-sponsored clinical trials, which offer people with a variety of medical conditions an opportunity to participate in the development of potential new treatment options.
Clinical trials are an integral part of a new drug or diagnostic discovery and development process as they provide evidence about the safety and efficacy of a medicine or diagnostic. They also provide important information about cost-effectiveness, clinical value, and impact on a patient’s quality of life.
Clinical research follows strict scientific standards to protect patients and help produce reliable study results. Studies are
The process can take upwards of 10 years, and according to the an
The Mississauga pharmaceutical Product Development site participates in patient-centric practices aimed at making trials more accessible and understandable to patients. Our study management teams have embedded patient-focused practices into the design and execution of our clinical trials, which have included the use of mobile home nurses who help increase trial participation for patients who are unable to come to regular site visits, as well as equipping patients with computers and tablets that disclose key study information related to their trial.
To learn more about clinical trials or to find a Roche-sponsored study, visit our
Roche believes that improving health outcomes for all patients is core to our mission, and we are committed to being industry leaders in delivering improved health outcomes for all.
In the increasingly diverse world around us, the time is now for research and clinical development to ensure greater inclusion of patients across racial and ethnic groups in support of optimizing health outcomes for all patients worldwide.
Because disease outcomes and drug responses can vary across populations, research must include patients who are racially, ethnically, and gender representative of those who experience disease. Roche is deeply committed to addressing barriers to clinical trial participation, diversifying genetic data for scientific discovery, and increasing access to innovative diagnostic and therapeutic solutions, by advancing inclusive research.
By building trusted partnerships with patients, providers and across the healthcare ecosystem, we can collectively combine scientific advances, new technologies and real-world data to drive scientific innovation and create new standards for inclusive research.
As we strive to deliver more patient benefit, we are passionately addressing healthcare disparities in order to deliver ever more personalized healthcare solutions for all patients.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
You are now leaving the website of Hoffmann-La Roche Ltd. ("Roche Canada"). Links to all external sites are provided as a resource to our visitors. Roche Canada assumes no responsibility for the content of these sites. Roche Canada has no control over these sites and the opinions, claims or comments contained in these sites should not be attributed to Roche Canada, unless otherwise specified.